This study aimed to evaluate current dosing patterns of GLP-1 RAs in France (FR) and the Netherlands (NL). Adult GLP-1 RA naïve T2D patients initiating liraglutide [LIRA], dulaglutide [DULA], or injectable semaglutide [SEMA]) between 4/1/2019-8/31/2019 in FR and 12/1/2018-8/31/2019 in NL (start dates based on SEMA availability) were identified using country-specific IQVIA Longitudinal Prescription Databases (LRx). The therapy initiation date was termed the ‘index date’. Patients were followed 6-months pre- and ≥6-months post-index. Average daily dose (ADD) or average weekly dose (AWD [ADD * 7]) during calendar year 2019 was assessed over the available follow-up while persistent (until discontinuation/switch). ADD was calculated as total units prescribed divided by days to next refill for a prescription. In a novel method, weighted ADD was assessed where a daily dose was assigned to each day based on the length of expected duration of a prescription. On-label dose changes were assessed over the fixed 6-month follow-up period. The study sample comprised 6,242 DULA, 3,572 LIRA, and 4,375 SEMA patients (across countries/cohorts: 45.5-52.9% male, median age 60-64 years, mean follow-up 7.7-10.6 months). The majority of DULA patients initiated 1.5mg (75.6% in FR/82.2% in NL), as recommended per European (EU) label for add-on therapy for non-vulnerable populations. Almost all SEMA patients initiated 0.25mg (92.3/97.1%) as per EU label. Mean doses were: LIRA ADD 1.55/1.59mg (weighted 1.31/1.39mg), DULA AWD 1.41/1.45mg (1.32/1.35mg), and SEMA AWD 0.58/0.67mg (0.51/0.57mg). Among SEMA patients, 44.0/48.9% increased dose to 1.0mg (mean of 71.6/78.9 days from index). Among LIRA patients, 6.6/19.7% increased dose to 1.8mg (mean of 78.4/82.8 days). Starting doses and ADD/AWD were within indicated label ranges. Less than half of patients reached the highest doses of SEMA or LIRA. Given the recent launch of SEMA, longer-term data is needed to better understand GLP-1 RA dosing patterns.